Cg Oncology Inc (CGON) Stock Price, Quote & News

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of pa...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 409 3700

Website: cgoncology.com

Address:

400 Spectrum Center Drive, Suite 2040, Irvine, United States

CapitalMonk Jun. 4 at 11:12 AM

$CGON Price: $54.42 (-2.00%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±5.76% RSI: 12.9 | Momentum: Strong Downside Volume: -1.0% vs avg Volatility: 3.17% Support: $54.02 | Resistance: $75.50 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/

0 · Reply

BIgBill374 Jun. 3 at 1:17 PM

$CGON so a tx for cancer is not good enough anymore maybe we need to say we treat AI cancer protection the machines

0 · Reply

Grinding10 Jun. 2 at 7:46 PM

$CGON fucking joke $20 off Highs what 2 weeks ago

0 · Reply

Grinding10 Jun. 2 at 4:12 PM

$CGON and there’s 3 months of stock progress after a positive readout not even the one we r waiting for; sure why not makes sense as usual 🖕

0 · Reply

justiceforb_85 Jun. 2 at 5:29 AM

$CGON adding. Look forward to pending PIVOT-006 data.

0 · Reply

Grinding10 Jun. 1 at 2:10 PM

$CGON been down what 14 out of 15 days WTF; am I missing something here; we get closer n closer this shits the bed

1 · Reply

TalkMarkets May. 29 at 9:22 PM

The S&P 500 Just Closed Its Eighth Straight Winning Week. #Healthcare Led The Charge. $CGON $IBRX $NVDA $SPY https://talkmarkets.com/article/the-sp-500-just-closed-its-eighth-straight-winning-week-healthcare-led-the-charge-1780089751

1 · Reply

ClassiTrader May. 29 at 3:53 PM

$CGON 🤑congrats callers

0 · Reply

justiceforb_85 May. 28 at 8:40 PM

$CGON added. Looking forward to P3 PIVOT-006 data this quarter.

2 · Reply

QuantInsider May. 26 at 7:40 PM

$CGON taking a hit with shares down about 4% today and over the last 5 days on the COO departure news Market's definitely on edge, repricing execution risk But check this out, three massive ask-side call blocks just printed at 9:46am We're talking 27,000 contracts, around $12.3M premium All in June and July strikes way OTM Seems like someone's betting big on upside, but this clashes with the bearish news Implied vol on the $90 June 18 calls is sitting at a hefty around 152% If you're thinking bullish, maybe consider vertical call spreads to keep risk in check Feels like a time for caution, not a clear bet Keep an eye on this

0 · Reply

CG Oncology Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 4:05 PM EDT - 7 days ago

CG Oncology to Present at Upcoming Investor Conferences in June

2026-05-26T15:52:04.000Z - 9 days ago

CG Oncology announces departure of president, COO Ambaw Bellete

2026-05-26T15:48:12.000Z - 9 days ago

Wolfe sees CG Oncology COO exit as operational, no impact to key programs

May 20, 2026, 2:35 PM EDT - 15 days ago

CG Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 8:00 AM EDT - 16 days ago

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

2026-05-19T10:11:37.000Z - 16 days ago

CG Oncology initiated with a Peer Perform at Wolfe Research

2026-05-15T12:54:43.000Z - 20 days ago

CG Oncology reports first results from CORE-008 Cohort CX

May 15, 2026, 8:00 AM EDT - 20 days ago

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

2026-05-14T14:06:13.000Z - 21 days ago

CG Oncology price target raised to $82 from $77 at Truist

May 12, 2026, 1:40 PM EDT - 23 days ago

CG Oncology Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 4:15 PM EDT - 24 days ago

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

2026-05-11T20:14:26.000Z - 24 days ago

CG Oncology price target raised to $81 from $79 at RBC Capital

2026-05-11T17:17:59.000Z - 24 days ago

CG Oncology price target raised to $80 from $77 at Wedbush

2026-05-11T13:48:59.000Z - 24 days ago

CG Oncology price target raised to $96 from $91 at JPMorgan

2026-05-10T14:30:50.000Z - 25 days ago

CG Oncology price target lowered to $83 from $84 at BofA

2026-05-08T17:07:16.000Z - 27 days ago

CG Oncology reports Q1 EPS (71c), consensus (54c)

May 8, 2026, 8:30 AM EDT - 27 days ago

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

May 8, 2026, 8:30 AM EDT - 27 days ago

CG Oncology Earnings release: Q1 2026

May 8, 2026, 8:30 AM EDT - 27 days ago

CG Oncology Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 weeks ago

CG Oncology to Present at Upcoming Investor Conferences in May

2026-04-27T12:19:01.000Z - 5 weeks ago

CG Oncology price target raised to $79 from $73 at RBC Capital

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

CG Oncology Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

CG Oncology Proxy statement: Proxy filing

2026-04-17T11:20:26.000Z - 6 weeks ago

JPMorgan ups CG Oncology target, adds ‘Positive Catalyst Watch’

JNJ

2026-04-14T11:50:44.000Z - 7 weeks ago

CG Oncology price target raised to $84 from $72 at BofA

2026-04-09T15:40:14.000Z - 2 months ago

JPMorgan healthcare analysts hold an analyst/industry conference call

TARA

2026-04-07T09:55:57.000Z - 2 months ago

CG Oncology price target raised to $100 from $80 at H.C. Wainwright

2026-03-26T13:06:58.000Z - 2 months ago

CG Oncology price target raised to $90 from $60 at UBS

2026-03-13T19:35:27.000Z - 2 months ago

CG Oncology price target raised to $72 from $65 at BofA

JNJ

Mar 2, 2026, 3:10 PM EST - 3 months ago

CG Oncology Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T17:20:16.000Z - 3 months ago

CG Oncology price target raised to $80 from $75 at H.C. Wainwright

Feb 27, 2026, 8:30 AM EST - 3 months ago

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

Feb 27, 2026, 8:30 AM EST - 3 months ago

CG Oncology Annual report: Q4 2025

Feb 27, 2026, 8:30 AM EST - 3 months ago

CG Oncology Earnings release: Q4 2025

Feb 27, 2026, 7:00 AM EST - 3 months ago

CG Oncology Slides: Investor presentation

Feb 23, 2026, 8:00 AM EST - 3 months ago

CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

Jan 15, 2026, 11:15 AM EST - 5 months ago

CG Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 6:00 PM EST - 5 months ago

CG Oncology Slides: Investor Presentation

Jan 9, 2026, 8:30 AM EST - 5 months ago

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

Jan 6, 2026, 8:00 AM EST - 5 months ago

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 8:30 AM EST - 6 months ago

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Nov 26, 2025, 7:00 AM EST - 6 months ago

CG Oncology Announces New Board Member and Board Transition

Nov 14, 2025, 8:00 AM EST - 7 months ago

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 8:00 AM EST - 7 months ago

CG Oncology Quarterly report: Q3 2025

Nov 14, 2025, 8:00 AM EST - 7 months ago

CG Oncology Earnings release: Q3 2025

Sep 9, 2025, 7:45 AM EDT - 9 months ago

CG Oncology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 5, 2025, 10:20 AM EDT - 9 months ago

CG Oncology Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 7:00 AM EDT - 9 months ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Sep 3, 2025, 8:00 AM EDT - 9 months ago

CG Oncology Completes Enrollment in PIVOT-006

Aug 8, 2025, 8:00 AM EDT - 10 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 8, 2025, 8:00 AM EDT - 10 months ago

CG Oncology Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 10 months ago

CG Oncology Earnings release: Q2 2025

Jun 10, 2025, 11:20 AM EDT - 1 year ago

CG Oncology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 5, 2025, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 11:30 AM EDT - 1 year ago

CG Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

CG Oncology Slides: Investor Presentation

May 13, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Transcript: Study Update

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Slides: Study Update

Apr 26, 2025, 4:10 PM EDT - 1 year ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Apr 25, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Proxy statement: Proxy Filing

Mar 28, 2025, 7:00 AM EDT - 1 year ago

CG Oncology Annual report: Q4 2024

Mar 28, 2025, 7:00 AM EDT - 1 year ago

CG Oncology Earnings release: Q4 2024

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Mar 5, 2025, 11:10 AM EST - 1 year ago

CG Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:10 AM EST - 1 year ago

CG Oncology Slides: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Dec 16, 2024, 4:05 PM EST - 1 year ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 12, 2024, 8:19 PM EST - 1 year ago

CG Oncology Announces Pricing of Public Offering

Dec 11, 2024, 7:00 AM EST - 1 year ago

CG Oncology Registration statement: Registration Filing

Dec 11, 2024, 7:00 AM EST - 1 year ago

CG Oncology Registration statement: Registration Filing

Dec 11, 2024, 6:17 AM EST - 1 year ago

CG Oncology Announces Proposed Public Offering

Dec 6, 2024, 1:18 PM EST - 1 year ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 8:00 AM EST - 1 year ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 5, 2024, 8:00 AM EST - 1 year ago

CG Oncology Transcript: Study Result

Dec 5, 2024, 8:00 AM EST - 1 year ago

CG Oncology Press release: Study Result

Dec 5, 2024, 8:00 AM EST - 1 year ago

CG Oncology Slides: Study Result

Dec 5, 2024, 7:00 AM EST - 1 year ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Nov 12, 2024, 7:00 AM EST - 1 year ago

CG Oncology Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

CG Oncology Earnings release: Q3 2024

Sep 6, 2024, 10:45 AM EDT - 1 year ago

CG Oncology Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 30, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 8:23 AM EDT - 1 year ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 6:00 AM EDT - 1 year ago

CG Oncology Quarterly report: Q2 2024

Aug 8, 2024, 6:00 AM EDT - 1 year ago

CG Oncology Earnings release: Q2 2024

Jun 6, 2024, 12:14 PM EDT - 2 years ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

May 24, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 2 years ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 7:00 AM EDT - 2 years ago

CG Oncology Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

CG Oncology Earnings release: Q1 2024

May 3, 2024, 4:30 PM EDT - 2 years ago

CG Oncology Transcript: Investor Update

May 3, 2024, 4:30 PM EDT - 2 years ago

CG Oncology Slides: Investor Update

May 3, 2024, 11:23 AM EDT - 2 years ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Apr 26, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 24, 2024, 10:00 AM EDT - 2 years ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Mar 28, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 2 years ago

CG Oncology Annual report: Q4 2023

Jan 30, 2024, 7:00 AM EST - 2 years ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 29, 2024, 8:14 AM EST - 2 years ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

Jan 26, 2024, 11:50 AM EST - 2 years ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 25, 2024, 1:46 PM EST - 2 years ago

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 7:51 AM EST - 2 years ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 24, 2024, 7:10 PM EST - 2 years ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

CapitalMonk Jun. 4 at 11:12 AM

0 · Reply

BIgBill374 Jun. 3 at 1:17 PM

$CGON so a tx for cancer is not good enough anymore maybe we need to say we treat AI cancer protection the machines

0 · Reply

Grinding10 Jun. 2 at 7:46 PM

$CGON fucking joke $20 off Highs what 2 weeks ago

0 · Reply

Grinding10 Jun. 2 at 4:12 PM

$CGON and there’s 3 months of stock progress after a positive readout not even the one we r waiting for; sure why not makes sense as usual 🖕

0 · Reply

justiceforb_85 Jun. 2 at 5:29 AM

$CGON adding. Look forward to pending PIVOT-006 data.

0 · Reply

Grinding10 Jun. 1 at 2:10 PM

$CGON been down what 14 out of 15 days WTF; am I missing something here; we get closer n closer this shits the bed

1 · Reply

TalkMarkets May. 29 at 9:22 PM

1 · Reply

ClassiTrader May. 29 at 3:53 PM

$CGON 🤑congrats callers

0 · Reply

justiceforb_85 May. 28 at 8:40 PM

$CGON added. Looking forward to P3 PIVOT-006 data this quarter.

2 · Reply

QuantInsider May. 26 at 7:40 PM

0 · Reply

Grinding10 May. 26 at 3:29 PM

$CGON Now $14 bucks from the high as it just gets closer to approval and more confirmation data; Makes sense as usual 🖕

0 · Reply

HelloHideki May. 25 at 1:09 PM

$CGON Has anyone looked at Oncolys BioPharma in Japan? CG Oncology has a multi-billion dollar valuation, while Oncolys is valued at only a fraction of that despite having reached commercialization stage in Japan. Interesting valuation gap.

0 · Reply

IronManResurrection May. 24 at 8:15 PM

IBRX direct competition from $CGON on the horizon in NMIBC. Fortunately for us it is yet another immunotherapy leaning on an augmented immune response. While they are targeted for a certain gene expression in BC and can activate the immune system they are not enhancing the base layer directly like Anktiva. That is the beauty of IL-15. No matter how sophisticated you make an engine, it still requires fuel. We are the immunological fuel for every variant of immunotherapy that exists and will come to exist. We don’t invent a lot of the drugs you take, WE MAKE THEM BETTER. Lympopenia and immune system boosting for the WIN!

0 · Reply

MarketBeat May. 21 at 2:04 AM

https://marketbeat.com/a/8665780/ $CGON CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

0 · Reply

Amscru80 May. 19 at 2:03 PM

$ICCM buy now or cry later, with great news!!! 🚀🚀🚀 $SLS $LLY $ABBV $CGON

0 · Reply

Quantumup May. 19 at 10:52 AM

Oppenheimer reit'd $URGN OP; $40 $CGON $TYRA Oppenheimer said: UroGen's investor event reinforced the commercial thesis for Zusduri in LG-IR-NMIBC, with the physician panel framing the drug as a potential paradigm shift from repeated surgeries (TURBT) toward office-based chemoablation. The most important incremental message was the degree of physician enthusiasm around broad use beyond the obvious advantages of avoiding repeated surgery. Doctors described Zusduri as easy to integrate operationally, increasingly reimbursable after permanent J-code implementation, patient-friendly relative to TURBT and conventional intravesical chemo, and appropriate for consideration among essentially all eligible recurrent patients. The panel also suggested that future competitors may face meaningful positioning hurdles unless they can offer overwhelmingly better efficacy, as Zusduri is first-to-market, requires no biomarker testing, can be used without TURBT, and has a finite six-dose treatment course.

0 · Reply

Grinding10 May. 18 at 4:30 PM

$CGON this is fucking bullshit; yeah now’s the time to sell 😃

1 · Reply

Quantumup May. 15 at 6:14 PM

BofA⬆️ $CGON's PT to $87 after⬆️its peak penetration in the BCG-Exposed setting, while reiterating Buy and saying—cohort CX data reinforces widespread value oppty. $URGN TARA MRK IBRX TYRA $JNJ Here's what BofA went on to say: https://x.com/Quantumup1/status/2055350522350080153?s=20

0 · Reply

VictoriaCapital May. 15 at 11:02 AM

$CGON Stepping back from the day-to-day volatility, the data emerging for cretostimogene continue to look very compelling. Durability, complete response rates, tolerability profile, and consistency across datasets all suggest this could become an important therapy for patients with NMIBC. The enthusiasm from many urologists also feels very real. That said, the key debate increasingly seems less about whether the therapy works and more about how quickly the regulatory path moves from here. The biggest question on my mind: What does the realistic BLA timing look like now? Because from a commercial and clinical perspective, every additional delay matters in a large market with high unmet need. Still, hard not to view the overall story positively: • Strong efficacy signals • Attractive bladder-sparing potential • Large addressable market • Significant physician interest • Potentially differentiated profile Will be very interesting to watch how FDA interactions evolve over the coming quarters.

2 · Reply

MarketBeat May. 15 at 7:08 AM

https://marketbeat.com/a/8655291/ $CGON CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears

0 · Reply

Grinding10 May. 14 at 4:41 PM

$CGON 🤷‍♂️yeah sure why not

0 · Reply

PlutoAnalyses May. 14 at 4:37 PM

Explore the complexities of the CANCER INDUSTRY. 1. Discover why every major pharmaceutical giant is racing to claim a stake in this booming market. 2. Set to skyrocket to a staggering 700 billion dollars by 2034, making it the biggest market for biotech. 3. 85% of drugs using the FDA's accelerated approval pathway are for cancer. 4. Cancer drugs cost triple the price of standard medications, even in tightly regulated countries, and the reasons go far beyond survival rates. Join the conversation and read the full article for free right here: https://open.substack.com/pub/plutoanalyses/p/inside-the-cancer-industry-navigating?r=5e6tza&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true $XBI , $IBB , $VSTM , $CHRS , $CGON

0 · Reply

Market Cap	4.80B
Revenue (ttm)	4.04M
Net Income (ttm)	-161.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,985.15%
Debt to Equity Ratio	0.00

Volume	653,900
Avg Vol	1,018,210
Day's Range	N/A - N/A
Shares Out	88.20M
Stochastic %K	18%
Beta	0.31
Analysts	Strong Sell
Price Target	$90.28